Deferred
Showing 1 to 3 of 3
| Title | Deferred ID | Guidance programme | Deferred date |
|---|---|---|---|
| Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [D5] | D5 | Technology appraisal guidance | |
| PillCam COLON 2 for investigation of the colon through direct visualisation | D6 | HealthTech guidance | |
| Teprotumumab for treating thyroid eye disease [ID6432] | D1 | Technology appraisal guidance |